Advertisement
Advertisement
TGTX
TG Therapeutics, Inc.
56.01
USDSponsored
+1.74
+3.21%
Aug 24, 16:00 UTC -4
Closed
After-Market
56.40
+0.39
+0.70%
TGTX Earnings Reports
Positive Surprise Ratio
TGTX beat 12 of 43 last estimates.
28%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$249.67M
/$0.40
Implied change from Q2 26 (Revenue/ EPS)
+3.89%
/+700.00%
Implied change from Q3 25 (Revenue/ EPS)
+54.40%
/+150.00%
TG Therapeutics, Inc. earnings per share and revenue
On Aug 03, 2026, TGTX reported earnings of 0.05 USD per share (EPS) for Q2 26, missing the estimate of 0.34 USD, resulting in a -85.48% surprise. Revenue reached 240.34 million, compared to an expected 234.32 million, with a 2.57% difference. The market reacted with a -11.26% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of 0.40 USD, with revenue projected to reach 249.67 million USD, implying an increase of 700.00% EPS, and increase of 3.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.11
Actual
$0.35
Surprise
+198.38%
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Alpha Cognition Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.40
Surprise
-0.05%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
PDS Biotechnology Corporation Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.18
Surprise
-35.75%
FAQ
What were TG Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, TG Therapeutics, Inc. reported EPS of $0.05, missing estimates by -85.48%, and revenue of $240.34M, 2.57% above expectations.
How did the market react to TG Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved down -11.26%, changed from $52.03 before the earnings release to $46.17 the day after.
When is TG Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for TG Therapeutics, Inc.'s next earnings report?
Based on 9
analysts, TG Therapeutics, Inc. is expected to report EPS of $0.40 and revenue of $249.67M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement